Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin

Fig. 2

Immunohistochemical analysis for ERCC1, RRM1, RRM2, and hENT-1 expression in malignant pleural mesothelioma patients. High and low nuclear expression for ERCC1 (a, b), and high and low cytoplasmic expression for RRM1 (d, e), RRM2 (g, h), and hENT-1 (j, k), respectively. Negative controls (without primary antibody) are shown for each molecule in c, f, i, and l, respectively

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us